News

Your contact person

Manager PR & Communications Jan Phillip Denkers

New Entity to Develop Therapeutics Targeting RAS Pathway Mutations in Colorectal Cancer (Picture: © Indivumed GmbH)

Indivumed Joins KHR Biotech

Indivumed GmbH (“Indivumed”) CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR ...

Read more …